143 related articles for article (PubMed ID: 33894494)
1. Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer.
Hsu CL; Tsai TH; Huang CK; Yang CY; Liao WY; Ho CC; Ruan SY; Chen KY; Shih JY; Yang PC
Lung Cancer; 2021 Jun; 156():50-58. PubMed ID: 33894494
[TBL] [Abstract][Full Text] [Related]
2. Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients Treated With First-Line EGFR Tyrosine Kinase Inhibitors.
Jiang T; Zhao J; Zhao C; Li X; Shen J; Zhou J; Ren S; Su C; Zhou C; O'Brien M
Clin Lung Cancer; 2019 Mar; 20(2):124-133.e2. PubMed ID: 30587399
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor-targeted immunomagnetic liposomes for circulating tumor cell enumeration in non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors.
Cui S; Ni Y; Zhao Y; Li Z; Xiong L; Liu J; Liang X; Jiang L
Lung Cancer; 2019 Jun; 132():45-53. PubMed ID: 31097093
[TBL] [Abstract][Full Text] [Related]
4. Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients.
Yang B; Qin A; Zhang K; Ren H; Liu S; Liu X; Pan X; Yu G
Oncol Res; 2017 Nov; 25(9):1601-1606. PubMed ID: 28474575
[TBL] [Abstract][Full Text] [Related]
5. A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.
Lindsay CR; Faugeroux V; Michiels S; Pailler E; Facchinetti F; Ou D; Bluthgen MV; Pannet C; Ngo-Camus M; Bescher G; Caramella C; Billiot F; Remon J; Planchard D; Soria JC; Besse B; Farace F
Ann Oncol; 2017 Jul; 28(7):1523-1531. PubMed ID: 28633480
[TBL] [Abstract][Full Text] [Related]
6. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
[TBL] [Abstract][Full Text] [Related]
7. A circulating tumor cell-based digital assay for the detection of EGFR T790M mutation in advanced non-small cell lung cancer.
Wang J; Sun N; Lee YT; Ni Y; Koochekpour R; Zhu Y; Tseng HR; Wang S; Jiang L; Zhu H
J Mater Chem B; 2020 Jul; 8(26):5636-5644. PubMed ID: 32525199
[TBL] [Abstract][Full Text] [Related]
8. The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
Ding PN; Becker TM; Bray VJ; Chua W; Ma YF; Lynch D; Po J; Luk AWS; Caixeiro N; de Souza P; Roberts TL
Lung Cancer; 2019 Aug; 134():187-193. PubMed ID: 31319980
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
Punnoose EA; Atwal S; Liu W; Raja R; Fine BM; Hughes BG; Hicks RJ; Hampton GM; Amler LC; Pirzkall A; Lackner MR
Clin Cancer Res; 2012 Apr; 18(8):2391-401. PubMed ID: 22492982
[TBL] [Abstract][Full Text] [Related]
10. Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer.
Ebert EBF; McCulloch T; Hansen KH; Linnet H; Sorensen B; Meldgaard P
Lung Cancer; 2020 Mar; 141():37-43. PubMed ID: 31945708
[TBL] [Abstract][Full Text] [Related]
11. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
[TBL] [Abstract][Full Text] [Related]
12. Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer.
Sun W; Yuan X; Tian Y; Wu H; Xu H; Hu G; Wu K
J Hematol Oncol; 2015 Jul; 8():95. PubMed ID: 26227959
[TBL] [Abstract][Full Text] [Related]
13. The application of nano-enrichment in CTC detection and the clinical significance of CTCs in non-small cell lung cancer (NSCLC) treatment.
Wei T; Zhu D; Yang Y; Yuan G; Xie H; Shen R
PLoS One; 2019; 14(7):e0219129. PubMed ID: 31344053
[TBL] [Abstract][Full Text] [Related]
14. [The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].
Li JM; Hu J; Bai CX; Zhang Y; Xu XB; Wang XD; Ding N
Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):778-782. PubMed ID: 30347549
[No Abstract] [Full Text] [Related]
15. Post-therapeutic circulating tumor cell-associated white blood cell clusters predict poor survival in patients with advanced driver gene-negative non-small cell lung cancer.
Wang Y; Liu Y; Zhang Z; Lu B; Gao Y; Tong L; Hu M; Lin PP; Li B; Zhang T
BMC Cancer; 2023 Jun; 23(1):578. PubMed ID: 37349714
[TBL] [Abstract][Full Text] [Related]
16. Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Matsumoto Y; Sawa K; Fukui M; Oyanagi J; Yoshimoto N; Suzumura T; Watanabe T; Kaneda H; Mitsuoka S; Asai K; Kimura T; Yamamoto N; Hirata K; Koh Y; Kawaguchi T
Lung Cancer; 2020 Jan; 139():80-88. PubMed ID: 31751804
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors.
Iwama E; Sakai K; Hidaka N; Inoue K; Fujii A; Nakagaki N; Ota K; Toyozawa R; Azuma K; Nakatomi K; Harada T; Hisasue J; Sakata S; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I
Cancer; 2020 Jan; 126(1):219-227. PubMed ID: 31503343
[TBL] [Abstract][Full Text] [Related]
18. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.
Beau-Faller M; Pencreach E; Leduc C; Blons H; Merlio JP; Bringuier PP; de Fraipont F; Escande F; Lemoine A; Ouafik L; Denis M; Hofman P; Lacave R; Melaabi S; Langlais A; Missy P; Morin F; Moro-Sibilot D; Barlesi F; Cadranel J;
Lung Cancer; 2020 Feb; 140():19-26. PubMed ID: 31841714
[TBL] [Abstract][Full Text] [Related]
19. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in
Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F
Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588
[TBL] [Abstract][Full Text] [Related]
20. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
